COMMUNIQUÉS West-GlobeNewswire

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

30/08/2017 - 07:02

REGULATED INFORMATION GHENT, Belgium, 30 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

30/08/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 30 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Abiomed annonce la démission de son Directeur financier et se réjouit du retour de son prédécesseur en qualité de consultant

30/08/2017 - 00:38

DANVERS, Massachusetts, le 28 août 2017 (GLOBE NEWSWIRE) - Abiomed, Inc. (NASDAQ : ABMD), un des plus grands fournisseurs de technologies innovantes d'assistance et de soin cardiaque, a annoncé aujourd'hui la démission [...]

Les données intermédiaires sur MobiusHD présentées à la Société européenne de cardiologie s'avèrent prometteuses dans le traitement de l'hypertension artérielle résistante

29/08/2017 - 20:53

MOUNTAIN VIEW, Californie, le 29 août 2017 (GLOBE NEWSWIRE) - Vascular Dynamics, Inc., (VDI), société privée de dispositifs médicaux qui développe de nouvelles solutions pour le traitement de l'hypertension artérielle, [...]

Solon Eiendom ASA - Primary insider notification

29/08/2017 - 17:53

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 29 August 2017) Per Knut Asphaug Bernhardt, personal assistant to the chairman of the board of Solon Eiendom [...]

Solon Eiendom ASA - Primary insider notification

29/08/2017 - 17:52

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 29 August 2017) Solon Eiendom ASA Financial Controller Arne Post has today bought 4,000 shares in Solon [...]

Solon Eiendom ASA - Primary insider notification

29/08/2017 - 17:51

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 29 August 2017) Solon Eiendom ASA CEO Andreas Martinussen (through his wholly owned company John Galt Invest [...]

Solon Eiendom ASA - Primary insider notification

29/08/2017 - 17:50

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 29 August 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]

RAMSAY GENERALE DE SANTE : résultats annuels au 30 juin 2017

29/08/2017 - 17:35

COMMUNIQUE DE PRESSE Paris, le 29 Août 2017 Résultats annuels à fin juin 2017 Des résultats résilients malgré une nouvelle année de baisse tarifaire Chiffre d'affaires annuel en hausse de 0.3% à 2 234,4 millions d'euros [...]

RAMSAY GENERALE DE SANTE : annual Results at the end of June 2017

29/08/2017 - 17:35

PRESS RELEASE Paris, 29 August 2017 Annual results at the end of June 2017 Strong performance despite a year of further price cuts Annual turnover up 0.3% to EUR 2,234.4 million (down 1.4% on a like-for-like basis) with [...]

Aino Health AB signs a deal with Hartela

29/08/2017 - 16:59

Aino Health Finland and Finnish construction company Hartela have signed a deal regarding Ainos extensive wellbeing services. The new agreement provides Hartela with an extensive part of Ainos wellbeing services. The [...]

Shire plc : Director/PDMR Shareholding

29/08/2017 - 16:30

Director/PDMR Shareholding August 29, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transaction by person discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Apricus Biosciences Files NDA Resubmission for Vitaros(TM)

29/08/2017 - 13:00

Approval Decision Expected in First Quarter 2018 SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and [...]

Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units

29/08/2017 - 10:01

Reference is made to the stock exchange notice of 18 August 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]

NxSE Forum 2017, Reunion Island (Indian Ocean), annual meeting of the African Tech

29/08/2017 - 09:03

On October 3, 4 and 5, the second NxSE edition (pronounce Nexi), the « International Digital Shift Forum - Indian Ocean & Africa » will be held in Reunion Island, a French department located in the Indian Ocean. [...]

Herantis Pharma Plc's half year financial report January 1 - June 30, 2017 (unaudited)

29/08/2017 - 08:00

Herantis Pharma Plc Company release August 29, 2017 at 9:00am Drug development progresses towards randomized trials Herantis Pharma Plc's half year financial report January 1 - June 30, 2017 (unaudited) Highlights in [...]

PCI Biotech: First half year 2017 report and presentation

29/08/2017 - 08:00

Oslo, 29 August 2017 - Please find enclosed the financial report and presentation for second quarter and first half year 2017. PCI Biotech reported important progress for the fima Chem programme during 1H 2017, with [...]

DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut

29/08/2017 - 07:30

Press Release Montrouge, France, August 29, 2017 DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut 93% of patients completing PEPITES opted to enroll in follow-up study [...]

DBV Technologies annonce la fin du recrutement de l'étude d'extension de phase III de Viaskin Peanut

29/08/2017 - 07:30

Communiqué de presse Montrouge, France, le 29 août 2017 DBV Technologies annonce la fin du recrutement de l'étude d'extension de phase III de Viaskin Peanut 93% des patients ayant terminé l'étude PEPITES ont choisi de [...]